<DOC>
	<DOC>NCT00240383</DOC>
	<brief_summary>A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes</brief_summary>
	<brief_title>Dose Ranging Study With LT, Monotherapy, PPAR</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>1. HbA1c &gt; 7.0% and â‰¤ 10.0% obtained at the Screening visit. 2. Men and women, 1870 years of age Established Type 2 diabetes 1. Symptomatic Type 2 diabetes defined as marked polyuria and polydipsia with greater than 10% weight loss during the last three months. 2. Administration of antihyperglycemic agents (other than thiazolidinediones) for more than three consecutive or a total of seven nonconsecutive days during the four weeks prior to screening. 3. Administration of thiazolidinediones for more than three consecutive or a total of seven nonconsecutive days during the six weeks prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>